Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) (GeparSepto)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Celgene Corporation
Roche Pharma AG
Information provided by (Responsible Party):
German Breast Group
ClinicalTrials.gov Identifier:
NCT01583426
First received: April 18, 2012
Last updated: October 11, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2018
  Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):